The Dermatology Digest

DECEMBER 4, 2024

Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Restem’s umbilical cord outer lining stem cells (ULSCs) program for the treatment of dermatomyositis (DM) and polymyositis (PM). The estimated incidence of PM/DM is approximately 5 to 22 cases per 100,000 individuals. PHOTO CREDIT: DermNet The post U.S.

Treatments 36

Treatments Office Therapy Clinic 36

The Dermatology Digest

FEBRUARY 14, 2024

VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. VTAMA cream, 1% data indicated no new safety or tolerability signals of concern in this population including children 2 years of age and older.

Dermatitis 74

Dermatitis Office Management Eczema 74

The Dermatology Digest

DECEMBER 18, 2024

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. “STEQEYMA is now the latest biologic in our immunology portfolio, joining ZYMFENTRA (infliximab-dyyb). .”

Portfolios 60

Portfolios Injections Office Safety 60

The Dermatology Digest

JANUARY 14, 2024

The PDE4 inhibitor is the first topical treatment for seborrheic dermatitis with a new mechanism of action in more than 20 years. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. There were no treatment-related Serious Adverse Events (SAEs). of the total study population).

Dermatitis 72

Dermatitis Office Dermatology Safety 72

The Dermatology Digest

NOVEMBER 4, 2024

The EU Medical Device Regulation (MDR) certification gave its nod to four injectable hyaluronic acid (HA) gel fillers from Evolus under the brand name Estyme, The CE Mark certification, through the new MDR process, represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe.

Injections 68

Injections Medical Portfolios Branding 68

The Dermatology Digest

SEPTEMBER 20, 2024

s Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT). Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s Dr. Robert B.

Office 74

Office Safety Clinic Medical 74

Aesthetics Advisor

OCTOBER 7, 2023

Based on rapidly emerging clinical trials evidence, the FLCCC team has developed the I-MASK+ protocol for prophylaxis and at home treatment of early stage COVID-19 and has now divided the I-MASK protocol into I-CARE and I-PREVENT protocols. Treatment is therefore highly stage-specific. Treatment of BA.4/BA.5/BQ.1.1

Treatments 69

Treatments Therapy Medical Vitamin C 69

The Dermatology Digest

MAY 16, 2024

Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, adds: “With only two FDA approved biologics, there is still an urgent need for new treatment options that treat all patient types and lesions, with the opportunity for inflammatory remission. HiSCR75 and beyond).

Safety 68

Safety Clinic Dermatology Office 68

The Dermatology Digest

FEBRUARY 26, 2024

Sonelokimab is a novel investigational nanobody for the treatment of inflammatory disease. This represents a crucial step in offering a potential innovative treatment option to patients and their dedicated physicians, addressing a condition that is often under-recognized, under-treated and significantly impacts patients’ lives.”

Office 74

Office Clinic Safety Innovations 74

Trillium Creek Dermatology

JANUARY 12, 2024

-invasive cosmetic treatments are a great way to achieve your aesthetic goals without undergoing intensive surgery with a long recovery period. The following are some of the most popular non-invasive treatments we offer at Trillium Creek: Botox Botox is one of the most popular and well-known cosmetic treatments.

Treatments 36

Treatments Eyebrow Shaping Chemical Peels Facials 36

The Dermatology Digest

JUNE 10, 2024

Food and Drug Administration (FDA) approved Almirall’s recent supplemental New Drug Application (sNDA) to expand the use area of tirbanibulin ( Klisyri) for the treatment of actinic keratosis (AK) on the face or scalp up to 100 cm 2.

Treatments 36

Treatments Safety Office Clinic 36

The Dermatology Digest

FEBRUARY 8, 2024

Psoriasis is also undergoing a revolution with the development of new oral treatments that act like injectable biologics, and this is of interest to patients who do not want a shot,” he says. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

Natural Beauty Med Spa

APRIL 28, 2024

Laser skin resurfacing is a popular cosmetic treatment that has the potential to drastically improve the appearance of the skin. However, you might be reluctant to commit to it due to concerns about safety. Another factor that should be kept in mind is the professional that performs the treatment. Is it worth it?

Med Spa 52

Med Spa Scarring Safety Makeup 52

North Dallas Dermatology Associates

NOVEMBER 1, 2023

By Juliet Gibson, MD The demand for cosmetic treatments has increased rapidly, resulting in a variety of options to reverse the effects of aging. The skill of the provider, and the area, can affect both your health and the overall outcome of the treatment. This added layer of safety provides peace of mind to patients.

Office 36

Office Safety Medical Training 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Jenni Nagle, L+A CO-Founder had a CO2 laser treatment and kept an eight day diary of her recovery process! For estheticians and skincare professionals, addressing pigmentation involves understanding and applying a multimodality treatment approach, which combines various techniques to tackle pigmentation through multiple mechanisms.

Chemical Peels 52

Chemical Peels Hyperpigmentation Vitamin C Microneedling 52

The Dermatology Digest

JULY 29, 2024

Key secondary endpoints will include PASI 90, PASI 100 and sPGA 0 measured at Weeks 16 and 24, and safety and tolerability. Patients completing Week 24 will have the opportunity to participate in a long-term extension (LTE) trial, ONWARD3, that will evaluate durability and maintenance of response and long-term safety.

Clinic 36

Clinic Safety Office Treatments 36

The Dermatology Digest

APRIL 18, 2024

Extra-strength 40U formulation of prabotulinumtoxinA-xvfs (Jeuveau, Evolus) performed well in a Phase 2 trial for the treatment of moderate to severe glabellar lines in adults. The safety profile was similar across all three arms and overall, 88.9% The safety profile was similar across all three arms and overall, 88.9%

Safety 36

Safety Office Surgery Dermatology 36

The Dermatology Digest

FEBRUARY 22, 2024

for the treatment of seborrheic keratoses. “We for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D., The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

FEBRUARY 22, 2024

for the treatment of seborrheic keratoses. “We for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D., The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

SEPTEMBER 12, 2024

In the confirmatory phase 3 study (LIBERTY-CUPID Study C), dupilumab met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines. At 24 weeks, efficacy among patients receiving Dupixent compared to placebo was as follows: 8.64-point

Safety 36

Safety Office Medical Dermatology 36

The Dermatology Digest

JANUARY 5, 2024

s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. The last patient has been dosed in Part 2 of Verrica Pharmaceuticals Inc.’s VP-315 is a chemotherapeutic administered intratumorally.

Pharmaceutical 36

Pharmaceutical Safety Office Clinic 36

The Dermatology Digest

JANUARY 5, 2024

Food and Drug Administration (FDA) seeking approval for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The NDA submission is based on positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea.

Rosacea 36

Rosacea Medical Office Safety 36

The Dermatology Digest

JANUARY 24, 2024

Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules in people with severe chronic hand eczema, according to results from the DELTA FORCE Trial, which is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.

Eczema 36

Eczema Safety Office Treatments 36

Fairlawn Aesthetic MD

JULY 19, 2023

It’s an innovative treatment in the field of aesthetic medicine that’s designed to help you look and feel your absolute best. The Cryo T-Shock procedure involves alternating cycles of cryo (cold) and thermo (heat) treatments applied directly to the skin. It’s a comfortable and safe treatment.

Treatments 36

Treatments Diet Consultation Consultations 36

The Dermatology Digest

JANUARY 11, 2024

Vtama cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, steroid-free, topical cream for both acute treatment and long-term management of AD. Vtama cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S.

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

The Dermatology Digest

APRIL 17, 2024

Patient enrollment is now complete in Celldex’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). Patients then enter a follow-up phase for an additional 24 weeks.

Safety 36

Safety Injections Therapy Office 36

The Dermatology Digest

JANUARY 20, 2024

By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch. Evommune, Inc.

Safety 36

Safety Office Dermatitis Clinic 36

New Age Spa Institute

APRIL 18, 2024

” Laser treatments for hair removal and skin rejuvenation are an often-connected part of the aesthetics industry, and there are some critical points to consider before pursuing a career in this field. This distinction is crucial for both practitioners and clients to understand, ensuring treatments are conducted safely and legally.

Legal 40

Legal Hair Removal Safety Esthetician 40

The Dermatology Digest

FEBRUARY 27, 2024

“The approval of SIMLANDI marks the first high-concentration, citrate-free biosimilar to Humira with IC status,” says Dr. Eric Hughes, Executive Vice President Global R&D and Chief Medical Officer at Teva, in a news release.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36

The Dermatology Digest

JANUARY 14, 2024

INTEGUMENT-1 and INTEGUMENT-2 (The INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis) were two identical Phase 3, parallel-group, double-blind, vehicle-controlled trials evaluating the safety and efficacy of roflumilast cream 0.15% in AD. Fully 91.5% Importantly, EASI-90 was observed in 22.4%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

AUGUST 21, 2024

The trial did not show a statistically significant difference between the proportion of patients treated with TMB-001 responding to treatment after 12 weeks compared with patients treated with vehicle. After encouraging phase 2b results, we observed an unexpectedly high vehicle response in this trial.

Pharmaceutical 36

Pharmaceutical Clinic Office Safety 36

Art of Dermatology

MAY 17, 2024

At Art of Dermatology at the Laser and Skin Surgery Center of New York, patient safety and satisfaction is Dr. Jessica Krant’s primary concern. Making sure you are seeing a board-certified core cosmetic specialty physician (dermatologist, plastic surgeon, oculoplastic surgeon, or ENT facial plastic surgeon) in a real medical office is key.

Office 36

Office Surgery Safety Injections 36

US Dermatologt Partners

MARCH 27, 2024

While dermatologists and research scientists haven’t decided on one name for this cutting-edge treatment, red light therapy is quickly gaining popularity thanks to the skin-rejuvenating results researchers are noting in research studies. Reduces cancer treatment side effects. Initially, treatment will take place several times a week.

Therapy 41

Therapy Treatments Dermatology Collagen 41

The Dermatology Digest

DECEMBER 27, 2023

has received approval from the University of Miami to enroll patients for its first-in-human Phase 2a clinical trial of HT-001 topical gel for the treatment of skin toxicities associated with EGFR inhibitors. Researchers will compare HT-001 to the placebo in the second period to see if HT-001 provides a significant treatment effect.

Office 36

Office Safety Ingredients Treatments 36

The Dermatology Digest

SEPTEMBER 30, 2024

s ESK-001 is a highly selective TYK2 inhibitor currently being evaluated in the Phase 3 ONWARD clinical program for the treatment of moderate-to-severe plaque psoriasis. Treatment emergent adverse event (TEAE) frequency and severity were similar across study arms, with the majority being mild-to-moderate and self-limited. Alumis Inc.’s

Safety 36

Safety Clinic Sustainability Office 36

The Studio Academy of Beauty

FEBRUARY 27, 2023

Career Opportunities: Becoming a facialist provides access to numerous job opportunities within the beauty industry including spas, salons, medical offices and more. This includes completing any required courses or workshops related to safety and sanitation practices, as well as any other topics specified by the board.

Continuing Education 52

Continuing Education Continuous Education Chemical Peels Sanitation 52

New Age Spa Institute

OCTOBER 12, 2023

link] Italian Influenced: CERVELLO, Bold Innovation in Laser hair Removal Treatment CERVELLO, an advanced next-generation diode platform, offers permanent hair reduction across three wavelengths suitable for all skin types: 808 nm, 755 nm, 1064 nm. Laser technology is continually advancing, leading to new and more effective treatments.

Hair Removal 52

Hair Removal Skin Types Skincare Brands Technology 52